ReviewClinical microbiology reviews2007
Bacteroides: the good, the bad, and the nitty-gritty.
Review in Clinical microbiology reviews, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03421301 (A Dietary Intervention With Functional Foods Reduce Metabolic Endotoxemia and Attenuates Biochemical Abnormalities in Subjects With Type 2 Diabetes by Modifying the Gut Microbiota.), which is not on this map. Cited by 1,102 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Dietary Intervention With Functional Foods Reduce Metabolic Endotoxemia and Attenuates Biochemical Abnormalities in Subjects With Type 2 Diabetes by Modifying the Gut Microbiota.
Who cites it
1,102 citing papers in PubMed, 5 syntheses or guidelines pooled it, 2,281 citations in OpenAlex.
- Metronidazole Susceptibility Patterns in EuropeanMedical sciences (Basel, Switzerland) · 2026Pooled it
- Dietary interventions and the gut microbiota: a systematic literature review of 80 controlled clinical trials.Journal of translational medicine · 2026Pooled it
- Meta-Analysis of the Gut Microbiome: An African American Representation.International journal of environmental research and public health · 2025Pooled it
- Evaluation of the Effect of Probiotic Supplementation on Intestinal Barrier Integrity and Epithelial Damage in Colitis Disease: A Systematic Review.Nutrition reviews · 2025Pooled it
- Microbiota-Focused Dietary Approaches to Support Health: A Systematic Review.The Journal of nutrition · 2025Pooled it
- Trial
- Bifidobacterium bifidum G9-1 Intake Improves Gastrointestinal Symptoms in Type 2 Diabetes Mellitus: An Open-Label, Randomized Controlled Trial (Binary STAR Study).Diabetes, obesity & metabolism · 2026Trial
- Mass azithromycin distribution and antibiotic resistance in the gut and nasopharynx: a cluster-randomized trial.Nature medicine · 2026Trial
- Lacticaseibacillus rhamnosus attenuates uremic toxins in patients with nondialysis chronic kidney disease through the anti-inflammatory molecules.Scientific reports · 2025Trial
- Controlled colonization of the human gut with a genetically engineered microbial therapeutic.Science (New York, N.Y.) · 2025Trial
- Underlying MASLD-induced gut microbiome dysbiosis and intestinal inflammation are key to poor outcomes in vibriosis infections in a preclinical model.Gut microbes · 2026Article
- Gene-level gut microbiome signatures as predictive biomarkers for response to immune checkpoint inhibitors across multiple cancer types.Gut microbes · 2026Article
- Characterization of the Middle Ear Microbiome in Meniere's Disease by 16S rRNA Gene Sequencing Compared to Chronic Suppurative Otitis Media.World journal of otorhinolaryngology - head and neck surgery · 2026Article
- Non-redundant cardiolipin synthase family proteins shape lipid composition and stress resilience inbioRxiv : the preprint server for biology · 2026Article
- Establishment of anmSystems · 2026Article
- In vitro study on the role of endoxylanase-driven fibre solubilisation and fibre particle size in improving fibre fermentation in broilers.Poultry science · 2026Article
- Bacterial small RNAs and extracellular vesicles in inflammatory and osteoimmune diseases: regulatory mechanisms and host-microbe communication.Archives of microbiology · 2026Review
- Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: A pilot single-arm trial.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026Article
- Gut Microbiota Differences in Wild Asian Elephants From Pu'er, China.Ecology and evolution · 2026Article
- Bacteroides fragilis Empyema Secondary to Ruptured Pyogenic Liver Abscess: A Rare Cause of Septic Shock.Cureus · 2026Article
1,042 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
summaryBacteroides species are significant clinical pathogens and are found in most anaerobic infections, with an associated mortality of more than 19%. The bacteria maintain a complex and generally beneficial relationship with the host when retained in the gut, but when they escape this environment they can cause significant pathology, including bacteremia and abscess formation in multiple body sites. Genomic and proteomic analyses have vastly added to our understanding of the manner in which Bacteroides species adapt to, and thrive in, the human gut. A few examples are (i) complex systems to sense and adapt to nutrient availability, (ii) multiple pump systems to expel toxic substances, and (iii) the ability to influence the host immune system so that it controls other (competing) pathogens. B. fragilis, which accounts for only 0.5% of the human colonic flora, is the most commonly isolated anaerobic pathogen due, in part, to its potent virulence factors. Species of the genus Bacteroides have the most antibiotic resistance mechanisms and the highest resistance rates of all anaerobic pathogens. Clinically, Bacteroides species have exhibited increasing resistance to many antibiotics, including cefoxitin, clindamycin, metronidazole, carbapenems, and fluoroquinolones (e.g., gatifloxacin, levofloxacin, and moxifloxacin).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.